ECRONICON OPEN ACCESS

EC MICROBIOLOGY
Review Article

Bacterial Metabolites in Liver Fibrosis: Integrating Metabolomics with Clinical Applications

Tamer A Addissouky[1,2,3,4]*

[1]*Medical Laboratories Techniques Department, College of Technology and Health Sciences, AL-Mustaqbal University, Hillah, Babylon, Iraq*

[2]*Department of Biochemistry, Science Faculty, Menoufia University, Menoufia, Egypt*

[3]*New burg El-Arab Hospital, Ministry of Health, Alexandria, Egypt*

[4]*American Society for Clinical Pathology (ASCP), Chicago, USA*

***Corresponding Author:** Tamer A Addissouky, Medical Laboratories Techniques Department, College of Technology and Health Sciences, AL-Mustaqbal University, Hillah, Babylon, Iraq and Science Faculty, Menoufia University, Egypt and New Burg El-Arab Hospital, Ministry of Health, Alexandria, Egypt and MLS, ASCP, Chicago, USA.

Received: February 10, 2025; **Published:** March 04, 2025

Abstract

Background: Liver fibrosis affects approximately 844 million people globally, representing a significant public health challenge. The gut-liver axis and its associated bacterial metabolites have emerged as crucial mediators in liver pathophysiology, offering new perspectives on disease progression and potential therapeutic interventions.

Purpose: This review aims to comprehensively analyze the role of bacterial metabolites in liver fibrosis, examining their mechanistic pathways, diagnostic potential, and therapeutic applications through advanced metabolomic approaches.

Methods and Findings: Recent advances in mass spectrometry and NMR spectroscopy have revealed complex interactions between bacterial metabolites and liver fibrosis progression. Key metabolites, including lipopolysaccharides (LPS), secondary bile acids, and short-chain fatty acids (SCFAs), demonstrate distinct mechanistic roles through specific pathways. LPS influences fibrogenesis via TLR4-mediated signaling and non-canonical inflammasome activation. Secondary bile acids modulate FXR and TGR5 signaling pathways, while SCFAs exhibit significant anti-inflammatory properties through GPR41/43 receptor activation and epigenetic modifications. Dysbiosis in liver disease manifests through reduced bacterial diversity, particularly affecting Lachnospiraceae and Ruminococcaceae families, with concurrent increases in Enterobacteriaceae. Integration of multi-omics approaches has identified novel metabolite signatures associated with disease progression, enabling the development of more accurate diagnostic biomarkers and personalized therapeutic strategies.

Conclusion: Understanding bacterial metabolites' role in liver fibrosis has revolutionized our approach to disease management, offering promising avenues for early detection and targeted therapy. While technical challenges and biological complexity persist, ongoing advances in metabolomic technologies and analytical approaches continue to enhance our ability to develop effective diagnostic and therapeutic strategies for liver fibrosis.

Keywords: *Gut-Liver Axis Dysbiosis; Bacterial Metabolomics; Liver Fibrogenesis; Metabolite-Based Therapeutics; Multi-Omics Integration*

Abbreviations

FXR: Farnesoid X Receptor; GPR41/43: G Protein-Coupled Receptor 41/43; LPS: Lipopolysaccharides; NMR: Nuclear Magnetic Resonance; SCFAs: Short-Chain Fatty Acids; TGR5: G Protein-Coupled Bile Acid Receptor 1; TLR4: Toll-Like Receptor 4

Article Highlights:

- Advanced metabolomic approaches reveal novel bacterial metabolite signatures in liver fibrosis, enabling early disease detection.
- Bacterial metabolites modulate liver fibrosis through multiple pathways, offering new therapeutic targeting opportunities.
- Integration of chronobiology and metabolomics provides innovative approaches for personalized treatment strategies.



Figure

Background

The global burden of liver fibrosis represents a significant public health challenge, affecting millions worldwide with increasing prevalence in both developed and developing nations. Recent epidemiological data indicates that approximately 844 million people suffer from chronic liver diseases, with fibrosis being a common pathological feature [1-6]. The emergence of the gut-liver axis as a critical mediator of liver pathophysiology has revolutionized our understanding of fibrosis progression. This bidirectional communication system, facilitated through multiple pathways including portal circulation, bile acids, and immune mediators, plays a pivotal role in maintaining liver homeostasis and disease development. Bacterial metabolites have emerged as key molecular mediators in this interaction, offering new insights into disease mechanisms and therapeutic opportunities. Despite advances in understanding these complex interactions, early detection and effective treatment of liver fibrosis remain significant challenges, necessitating innovative approaches to disease management [7-11].

Gut microbiota-liver axis: Contemporary understanding

The anatomical and functional relationship between the gut and liver represents a sophisticated biological framework essential for maintaining physiological homeostasis. Portal circulation dynamics facilitate the transport of approximately 70% of the liver's blood supply from the intestines, creating a direct route for bacterial metabolites and other gut-derived factors. This unique circulatory system enables continuous monitoring of gut-derived products while simultaneously exposing the liver to potential pathogenic factors during dysbiosis. Bile acid circulation functions as a critical signaling pathway, with primary bile acids undergoing bacterial transformation in the intestine to create secondary bile acids that influence both hepatic and intestinal function. The immune system interactions within this axis involve complex networks of innate and adaptive immune cells responding to microbial signals and metabolites [12-16]. Dysbiosis

in liver disease manifests through distinct taxonomic alterations, characterized by reduced bacterial diversity and altered abundance of key phyla. Recent studies have identified significant reductions in beneficial bacteria such as Lachnospiraceae and Ruminococcaceae families, with concurrent increases in potentially pathogenic Enterobacteriaceae. These changes carry profound functional implications for metabolite production and immune regulation. Advanced metabolomic analyses have revealed novel signatures associated with liver fibrosis progression, including alterations in aromatic amino acid metabolism and short-chain fatty acid production patterns [17-20].

Bacterial metabolites in liver fibrosis

Lipopolysaccharides (LPS) play a central role in liver fibrosis progression through their interaction with host immune responses as presented in table 1. The structure of LPS, comprising lipid A, core oligosaccharide, and O-antigen, determines its biological activity and interaction with host receptors. TLR4-mediated signaling represents the primary pathway through which LPS promotes fibrogenesis, activating hepatic stellate cells and triggering inflammatory cascades. Recent discoveries have highlighted novel aspects of LPS-induced fibrogenesis, including the role of non-canonical inflammasome activation and oxidative stress pathways. These findings have led to the identification of new therapeutic targets, including TLR4 antagonists and LPS-neutralizing agents [21-24].

Secondary bile acids emerge from bacterial transformation of primary bile acids through deconjugation, oxidation, and dehydroxylation processes. These metabolites activate FXR and TGR5 signaling pathways, influencing metabolism, inflammation, and fibrosis progression. Metabolomic signatures of bile acid populations have revealed distinct patterns associated with different stages of liver fibrosis. The therapeutic implications of bile acid signaling have led to the development of synthetic agonists and modulators of bile acid receptors for treating liver fibrosis [25-28].

Short-chain fatty acids (SCFAs) represent crucial metabolites produced through bacterial fermentation of dietary fiber. The primary production pathways involve complex interactions between different bacterial species, resulting in acetate, propionate, and butyrate generation. These metabolites signal through GPR41/43 receptors, influencing various cellular processes including inflammation and metabolism. Recent research has uncovered important epigenetic modifications induced by SCFAs, affecting gene expression patterns in hepatic cells. The anti-inflammatory properties of SCFAs, particularly butyrate, offer promising therapeutic potential for liver fibrosis [29-32].

Metabolite	Primary Source	Key Signaling Pathways	Cellular Effects	Potential Therapeutic Implications
Lipopolysaccharides (LPS)	Gram-negative Bacteria	TLR4-mediated signaling	- Hepatic stellate cell activation - Inflammatory cascade trigger - Non-canonical inflammasome activation	- TLR4 antagonists - LPS-neutralizing agents - Targeted inflammatory intervention
Secondary Bile Acids	Bacterial transformation of primary bile acids	FXR and TGR5 receptor activation	- Metabolism regulation - Inflammation modulation - Fibrosis progression	- Synthetic bile acid receptor agonists - Targeted metabolic interventions - Personalized receptor modulation
Short-Chain Fatty Acids (SCFAs)	Bacterial fermentation of dietary fiber	GPR41/43 receptor signaling	- Anti-inflammatory properties - Epigenetic modifications - Cellular metabolism regulation	- SCFA supplementation - Microbiota engineering - Epigenetic therapeutic approaches

Table 1: *Bacterial metabolites in liver fibrosis: mechanistic pathways and interactions.*

Advanced metabolomic approaches

Technological advances in metabolomics have revolutionized our understanding of bacterial metabolites in liver fibrosis as presented in table 1. Mass spectrometry innovations now enable detection of thousands of metabolites with unprecedented sensitivity and specificity. High-resolution mass spectrometry platforms, particularly those utilizing ion mobility separation, provide enhanced metabolite identification capabilities. NMR spectroscopy applications offer complementary insights through non-destructive analysis of metabolite structures and concentrations in complex biological matrices. Multi-omics integration approaches combine metabolomic data with genomic, transcriptomic, and proteomic information, providing comprehensive understanding of disease mechanisms [33-38].

Biomarker discovery efforts have yielded promising results through sophisticated analytical approaches. Novel metabolite panels incorporating multiple bacterial metabolites demonstrate improved diagnostic accuracy compared to traditional markers. Machine learning applications have enhanced pattern recognition in complex metabolomic datasets, identifying previously unknown metabolite signatures associated with fibrosis progression. Validation strategies incorporating multiple cohorts and standardized analytical protocols have strengthened the reliability of identified biomarkers [39,40].

Omics Approach	Key Technological Platforms	Analytical Capabilities	Potential Insights	Challenges
Metabolomics	- High-resolution Mass Spectrometry - Ion Mobility Separation - NMR Spectroscopy	- Metabolite identification - Concentration quantification - Structural characterization	- Disease progression markers - Personalized diagnostic signatures - Therapeutic target identification	- Complex biological matrices - Metabolite structural similarities - Quantification accuracy
Genomics Integration	- Next-Generation Sequencing - Whole Genome Analysis	- Genetic variation mapping - Inheritance pattern analysis	- Genetic predisposition markers - Host-microbe interaction mechanisms	- Genetic complexity - Variable penetrance
Transcriptomics	- RNA Sequencing - Microarray Technologies	- Gene expression profiling - Regulatory network analysis	- Metabolite-induced gene changes - Inflammatory response mechanisms	- Technical noise - Sample heterogeneity
Proteomics	- Mass Spectrometry-based Proteomics - Targeted Protein Analysis	- Protein interaction mapping - Post-translational modification detection	- Metabolite-protein interactions - Cellular response mechanisms	- Dynamic protein landscape - Limited detection sensitivity

Table 2: *Multi-omics integration strategies in liver fibrosis metabolomics.*

Clinical applications

Diagnostic biomarkers derived from bacterial metabolites offer new opportunities for disease monitoring and management. Early detection strategies utilize combinations of metabolites showing altered patterns before conventional markers become abnormal. Disease progression monitoring benefits from longitudinal metabolomic profiling, enabling dynamic assessment of fibrosis development. Treatment response assessment through metabolomic analysis provides rapid feedback on therapeutic efficacy, allowing for personalized treatment adjustments [41-44].

Therapeutic interventions targeting bacterial metabolites represent an emerging frontier in liver fibrosis treatment. Targeted metabolite modulation approaches include selective inhibition of harmful metabolites and enhancement of beneficial ones. Microbiota engineering strategies utilize synthetic biology approaches to modify bacterial metabolite production. Novel drug development efforts focus on metabolite-based therapeutics and pathway modulators. Personalized approaches incorporate individual metabolomic profiles to guide treatment selection and monitoring [45-48].

Emerging research areas

Metabolite-immune system interactions represent a critical area of investigation in liver fibrosis. Innate immunity responses to bacterial metabolites involve complex interactions with pattern recognition receptors and inflammatory mediators. Adaptive immunity modifications by metabolites include effects on T cell differentiation and function. Immunometabolism research reveals how bacterial metabolites influence immune cell metabolism and function in the context of liver fibrosis [49,50].

Circadian rhythm effects on bacterial metabolite production and function have emerged as important regulators of liver physiology. Temporal metabolite variations follow distinct patterns influenced by host and microbial circadian rhythms. Chronotherapeutic opportunities arise from understanding these temporal patterns, enabling optimized timing of therapeutic interventions [51,52].

Environmental influences significantly impact bacterial metabolite profiles and their effects on liver fibrosis. Diet-metabolite interactions demonstrate how dietary components influence bacterial metabolism and metabolite production. Xenobiotic effects include both direct impacts on bacterial metabolism and indirect effects through host response modifications. Stress responses alter bacterial metabolite production patterns and host susceptibility to fibrosis [53-56].

Future Directions

Technical advances continue to expand our capabilities in metabolite analysis and understanding. Single-cell metabolomics provides unprecedented resolution of metabolite distributions and cellular responses. Spatial metabolomics techniques reveal metabolite localization patterns within liver tissue. Real-time monitoring technologies enable dynamic assessment of metabolite changes during disease progression [57,58]. Clinical translation efforts focus on moving promising findings toward practical applications. Biomarker validation studies incorporate larger cohorts and diverse populations to establish clinical utility. Therapeutic development pathways explore novel metabolite-based treatments and combination approaches. Prevention strategies utilize metabolomic insights to identify modifiable risk factors and intervention opportunities [59].

Methodological considerations

Sample collection and processing protocols significantly influence metabolomic analysis quality. Standardization protocols ensure consistency across studies and laboratories. Quality control measures incorporate internal standards and reference materials. Data reproducibility efforts address technical and biological variation sources [60]. Data analysis approaches continue to evolve with technological advances. Bioinformatics approaches incorporate machine learning and artificial intelligence tools for pattern recognition. Statistical considerations address multiple testing issues and validation requirements. Integration strategies combine multiple data types to enhance biological insight [61].

Challenges and Limitations

Technical challenges persist in metabolomic analysis of bacterial metabolites. Metabolite identification remains complicated by structural similarities and complex matrices. Quantification accuracy depends on appropriate standards and calibration methods. Data interpretation requires sophisticated computational approaches and biological knowledge [62]. Biological complexity presents additional challenges in understanding metabolite roles. Host-microbe interactions involve multiple feedback loops and regulatory mechanisms.

Temporal dynamics of metabolite production and degradation complicate analysis. Individual variation in metabolite responses necessitates personalized approaches to diagnosis and treatment [63].

Conclusion

The comprehensive analysis of bacterial metabolites in liver fibrosis has revealed intricate relationships between gut microbiota and hepatic pathophysiology, fundamentally changing our understanding of disease progression and treatment approaches. The integration of advanced metabolomic techniques with multi-omics data has identified novel biomarkers and therapeutic targets, particularly through the characterization of LPS, secondary bile acids, and SCFAs pathways. While significant progress has been made in understanding these complex interactions, challenges remain in metabolite identification, quantification accuracy, and data interpretation. Future directions point toward the development of single-cell metabolomics, spatial metabolomics, and real-time monitoring technologies, which promise to further elucidate the dynamic nature of metabolite-mediated processes in liver fibrosis.

Recommendations

To advance the field of bacterial metabolomics in liver fibrosis, we recommend prioritizing the standardization of sample collection and processing protocols across laboratories to ensure data reproducibility and reliability. Implementation of artificial intelligence and machine learning approaches should be expanded to enhance pattern recognition in complex metabolomic datasets. Clinical validation studies should incorporate diverse patient populations and longitudinal sampling to establish robust biomarker panels. Development of targeted therapeutic approaches should focus on personalized interventions based on individual metabolomic profiles, while considering circadian rhythm effects and environmental influences. Additionally, we recommend increased focus on developing cost-effective, high-throughput screening methods for metabolite analysis to facilitate clinical translation.

Ethical Approval and Consent to Participate

Not applicable.

Clinical Trial Number

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Materials

All data are available and sharing is available as well as publication.

Competing Interests

The author hereby that they have no competing interests.

Funding Support

Corresponding author supplied all study materials. There was no further funding for this study.

Authors' Contributions

The corresponding author completed the study protocol and was the primary organizer of data collection and the manuscript's draft and revision process. The corresponding author wrote the article and ensured its accuracy.

Acknowledgements

The author thanks all the researchers who have made great efforts in their studies. Moreover, we are grateful to this journal's editors, reviewers, and readers.

Bibliography

1. Wong CR., *et al*. "Prevalence of healthcare barriers among us adults with chronic liver disease compared to other chronic diseases". *Gastro Hep Advances* 3.6 (2023): 796-808.
2. Zheng S., *et al*. "Liver cirrhosis: Current status and treatment options using western or traditional Chinese medicine". *Frontiers in Pharmacology* 15 (2024): 1381476.
3. Addissouky TA. "From reactive to proactive: advances leading the paradigm shift in cholecystitis management". *Research in Molecular Medicine* 11.3 (2023): 161-176.
4. Addissouky TA. "From molecular mechanisms to precision medicine: Transformative approaches in cirrhosis management". *Archives of Stem Cell and Therapy* 5.1 (2024): 22-31.
5. Addissouky TA. "Personalized pain pathways in liver fibrosis: towards precision hepatology". *Avicenna Journal of Medical Biochemistry* 12.2 (2024): 162-171.
6. Addissouky TA. "Next generation of colorectal cancer management: integrating omics, targeted therapies, and smart technologies". *Avicenna Journal of Medical Biochemistry* 12.2 (2024): 131-143.
7. Ronca V., *et al*. "The liver as a central "hub" of the immune system: Pathophysiological implications". *Physiological Reviews* 105.2 (2025): 493-539.
8. Zou J., *et al*. "Neuroimmune modulation in liver pathophysiology". *Journal of Neuroinflammation* 21.1 (2024): 188.
9. Mohanty I., *et al*. "The changing metabolic landscape of bile acids - keys to metabolism and immune regulation". *Nature Reviews Gastroenterology and Hepatology* 21.7 (2024): 493-516.
10. Addissouky TA. "Polyploidy-mediated resilience in hepatic aging: Molecular mechanisms and functional implication". *Egyptian Liver Journal* 14.1 (2024): 83.
11. Addissouky TA. "Liver stiffness as a dynamic predictor of decompensation and mortality in alcohol-related liver disease". *Discovery Medicine* 1 (2024): 96.
12. Liu X., *et al*. "Fundamental role of brain-organ interaction in behavior-driven holistic homeostasis". Fundamental Research (2024).
13. Yuan H., *et al*. "Biomarkers for health functional foods in metabolic dysfunction-associated steatotic liver disorder (MASLD) prevention: An integrative analysis of network pharmacology, gut microbiota, and multi-omics". *Nutrients* 16.18 (2023): 3061.
14. Addissouky TA. "Translating molecular heterogeneity into precision medicine for advanced liver disease". *Archives of Gastroenterology Research* 5.1 (2024): 47-58.
15. Addissouky TA., *et al*. "Latest advances in hepatocellular carcinoma management and prevention through advanced technologies". *Egyptian Liver Journal* 14.2 (2024).
16. Addissouky TA., *et al*. "Translational insights into molecular mechanisms of chemical hepatocarcinogenesis for improved human risk assessment". *Advances in Clinical Toxicology* 9.1 (2024): 294.

17. Yang Y., *et al*. "Polysaccharide-mediated modulation of gut microbiota in the treatment of liver diseases: Promising approach with significant challenges". *International Journal of Biological Macromolecules* 280.1 (2024): 135566.

18. Sharma SP., *et al*. "Gut microbiome and metabolome signatures in liver cirrhosis-related complications". *Clinical and Molecular Hepatology* 30.4 (2024): 845-862.

19. Addissouky TA., *et al*. "Preclinical promise and clinical challenges for innovative therapies targeting liver fibrogenesis". *Archives of Gastroenterology Research* 4.1 (2023): 14-23.

20. Addissouky TA., *et al*. "Transforming screening, risk stratification, and treatment optimization in chronic liver disease through data science and translational innovation". *The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy* 25.1 (2024): 53-62.

21. Li Z., *et al*. "The double roles of T cell-mediated immune response in the progression of MASLD". *Biomedicine and Pharmacotherapy* 173 (2024): 116333.

22. Chen L., *et al*. "Interactions between toll-like receptors signaling pathway and gut microbiota in host homeostasis". *Immunity, Inflammation and Disease* 12.7 (2024): e1356.

23. Addissouky TA., *et al*. "*Schisandra chinensis* in liver disease: exploring the mechanisms and therapeutic promise of an ancient Chinese botanical". *Archives of Pharmacology and Therapeutics* 6.1 (2024): 27-33.

24. Addissouky TA., *et al*. "Realizing the promise of artificial intelligence in hepatocellular carcinoma through opportunities and recommendations for responsible translation". *Jurnal Online Informatika* 9.1 (2024): 70-79.

25. Ridlon JM and Gaskins HR. "Another renaissance for bile acid gastrointestinal microbiology". *Nature Reviews Gastroenterology and Hepatology* 21.5 (2024): 348-364.

26. He S., *et al*. "Bile acid and its bidirectional interactions with gut microbiota: a review". *Critical Reviews in Microbiology* 50.5 (2023): 684-701.

27. Addissouky TA., *et al*. "Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis". *Egyptian Journal of Internal Medicine* 36 (2024): 19.

28. Addissouky TA., *et al*. "Bending the curve through innovations to overcome persistent obstacles in HIV prevention and treatment". *Journal of AIDS and HIV Treatment* 6.1 (2024): 44-53.

29. Mahalak KK., *et al*. "Supplementation with soluble or insoluble rice-bran fibers increases short-chain fatty acid producing bacteria in the gut microbiota *in vitro*". *Frontiers in Nutrition* 11 (2024): 1304045.

30. Pi X., *et al*. "Bacterial, short-chain fatty acid and gas profiles of partially hydrolyzed guar gum *in vitro* fermentation by human fecal microbiota". *Food Chemistry* 430 (2023): 137006.

31. Addissouky TA., *et al*. "Optical insights into fibrotic livers: applications of near-infrared spectroscopy and machine learning". *Archives of Gastroenterology Research* 5.1 (2024): 1-10.

32. Addissouky TA., *et al*. "Can vaccines stop cancer before it starts? assessing the promise of prophylactic immunization against high-risk preneoplastic lesions". *Journal of Cellular Immunology* 5.4 (2023): 127-140.

33. Sharma SP., *et al*. "Gut microbiome and metabolome signatures in liver cirrhosis-related complications". *Clinical and Molecular Hepatology* 30.4 (2024): 845-862.

34. Yuan H., *et al*. "Biomarkers for health functional foods in metabolic dysfunction-associated steatotic liver disorder (MASLD) prevention: an integrative analysis of network pharmacology, gut microbiota, and multi-omics". *Nutrients* 16.18 (2023): 3061.

35. Tang J., *et al*. "Intestinal microbiota promoted NiONPs-induced liver fibrosis via effecting serum metabolism". *Ecotoxicology and Environmental Safety* 270 (2024): 115943.

36. Addissouky TA., *et al*. "Oxidative stress and inflammation: elucidating mechanisms of smoking-attributable pathology for therapeutic targeting". *Bulletin of the National Research Centre* 48 (2024): 16.

37. Addissouky TA. "Nanopore sequencing of cell-free DNA: An emerging liquid biopsy approach for brain tumor molecular profiling". *Journal of Experimental Pathology* 5.1 (2024): 49-60.

38. Addissouky TA. "Emerging therapeutics targeting cellular stress pathways to mitigate end-organ damage in type 1 diabetes". *Avicenna Journal of Medical Biochemistry* 12.1 (2024): 39-46.

39. Rakhshaninejad M., *et al*. "Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach". *BMC Bioinformatics* 25.1 (2024): 33.

40. Addissouky TA. "Precision medicine for personalized cholecystitis care: integrating molecular diagnostics and biotherapeutics". *Bulletin of the National Research Centre* 48 (2024): 89.

41. Wasilewski T., *et al*. "AI-assisted detection of biomarkers by sensors and biosensors for early diagnosis and monitoring". *Biosensors* 14.7 (2024): 356.

42. Haghayegh F., *et al*. "Revolutionary point-of-care wearable diagnostics for early disease detection and biomarker discovery through intelligent technologies". *Advanced Science* 11.36 (2024): 2400595.

43. Addissouky TA., *et al*. "Recent advances in diagnosing and treating *Helicobacter pylori* through botanical extracts and advanced technologies". *Archives of Pharmacology and Therapeutics* 5.1 (2023): 53-66.

44. Addissouky TA., *et al*. "Recent trends in *Helicobacter pylori* management: harnessing the power of AI and other advanced approaches". *Beni-Suef University Journal of Basic and Applied Sciences* 12 (2023): 80.

45. Bernardi F., *et al*. "Gut microbiota metabolites: unveiling their role in inflammatory bowel diseases and fibrosis". *Pharmaceuticals* 17.3 (2024): 347.

46. Wang Y., *et al*. "Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma". *Frontiers in Pharmacology* 14 (2024): 1336216.

47. Addissouky TA. "The global threat of multidrug-resistant pathogens: a call for action". *EC Microbiology* 20.11 (2024): 01-09.

48. Addissouky TA., *et al*. "Recent developments in the diagnosis, treatment, and management of cardiovascular diseases through artificial intelligence and other innovative approaches". *Journal of Biomedical Research* 5.1 (2024): 29-40.

49. Dong Y., *et al*. "The mechanism of gut-lung axis in pulmonary fibrosis". *Frontiers in Cellular and Infection Microbiology* 14 (2024): 1258246.

50. Addissouky TA., *et al*. "Towards personalized care: Unraveling the genomic and molecular basis of sepsis-induced respiratory complications". *Archives of Clinical Toxicology* 6.1 (2024): 4-15.

51. Xie X., *et al*. "Regulation of metabolism by circadian rhythms: Support from time-restricted eating, intestinal microbiota and omics analysis". *Life Sciences* 351 (2024): 122814.

52. Addissouky TA., *et al*. "Emerging biomarkers for precision diagnosis and personalized treatment of cystic fibrosis". *Journal of Rare Diseases* 3 (2024): 28.

53. Adhikary S., *et al*. "Impacts of gut microbiota alteration on age-related chronic liver diseases". *Digestive and Liver Disease* 56.1 (2023): 112-122.

54. Addissouky TA. "Unraveling the molecular signatures of lupus-associated osteoarthritis: a comprehensive review of novel biomarker strategies". *Clinical Orthopaedic and Trauma Care* 6.7 (2024): 1-9.

55. Addissouky TA. "Nanocarrier-mediated drug delivery in rheumatoid arthritis: overcoming therapeutic limitations through targeted approaches". *Clinical Orthopaedic and Trauma Care* 6.7 (2024).

56. Addissouky TA. "Revolutionizing total knee arthroplasty: the integration and impact of artificial intelligence across the care continuum". *Clinical Orthopaedic and Trauma Care* 6.7 (2024).

57. Bibri SE., *et al*. "Artificial intelligence of things for synergizing smarter eco-city brain, metabolism, and platform: Pioneering data-driven environmental governance". *Sustainable Cities and Society* 108 (2024): 105516.

58. Addissouky TA. "The gut-liver axis and gut dysbiosis: implications for liver health and disease". *EC Microbiology* 21.1 (2025): 01-10.

59. Bozuyuk U., *et al*. "Roadmap for clinical translation of mobile microrobotics". *Advanced Materials* 36.23 (2024): e2311462.

60. Shaik A., *et al*. "Influence of epinephrine reactivity to stress on meat quality in goats". *Translational Animal Science* 8 (2023): txae078.

61. Ochulor Joshua., *et al*. "Technological innovations and optimized work methods in subsea maintenance and production". *Engineering Science and Technology Journal* 5.5 (2024): 1627-1642.

62. Feng Y., *et al*. "The potential new microbial hazard monitoring tool in food safety: Integration of metabolomics and artificial intelligence". *Trends in Food Science and Technology* 149 (2024): 104555.

63. Chakraborty S., *et al*. "Multi-OMICS approaches in cancer biology: New era in cancer therapy". *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1870.5 (2024): 167120.

Volume 21 Issue 3 March 2025